Skip to main content

Calcipotriene topical Disease Interactions

There is 1 disease interaction with calcipotriene topical.


Calcipotriene topical (applies to calcipotriene topical) hypercalcemia

Major Potential Hazard, High plausibility. Applicable conditions: Poisoning by Vitamins

The use of calcipotriene topical preparations is contraindicated in patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcipotriene is a synthetic vitamin D3 analog. Systemic absorption of topically applied calcipotriene ranges from less than 1% for the scalp solution to 5% to 6% for the ointment. Calcipotriene has been reported to be 100 to 200 times less potent in its effects on calcium utilization than natural vitamin D, which facilitates the absorption of calcium in the intestine. Transient, rapidly reversible elevation of serum calcium has been reported following the topical administration of calcipotriene. If elevation in serum calcium outside the normal range occurs, treatment should be discontinued until normal calcium levels are restored. Patients should be advised to contact their physician if they experience early symptoms of hypercalcemia such as weakness, fatigue, somnolence, headache, anorexia, dry mouth, metallic taste, nausea, vomiting, abdominal cramps, constipation, diarrhea, vertigo, tinnitus, ataxia, exanthema, muscle pain, bone pain, and irritability.


  1. Hardman KA, Heath DA, Nelson HM (1993) "Hypercalcaemia associated with calcipotriol (Dovonex) treatment." BMJ, 306, p. 896
  2. Berth-Jones J, Bourke JF, Iqbal SJ, Hutchinson PE (1993) "Urine calcium excretion during treatment of psoriasis with topical calcipotriol." Br J Dermatol, 129, p. 411-4
  3. Bourke JF, Berth-Jones J, Iqbal SJ, Hutchinson PE (1993) "High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris." Br J Dermatol, 129, p. 74-6
  4. Dubertret L, Wallach D, Souteyrand P, Perussel M, Kalis B, Meynadier J, Chevrant-Breton J, Beylot C, Bazex JA, Jurgensen HJ (1992) "Efficacy and safety of calcipotriol (MC 903) ointment in psoriasis vulgaris. A randomized, double-blind, right/left comparative, vehicle- controlled study." J Am Acad Dermatol, 27, p. 983-8
  5. Dwyer C, Chapman RS (1991) "Calcipotriol and hypercalcaemia." Lancet, 338, p. 764-5
  6. Mortensen L, Kragballe K, Wegmann E, Schifter S, Risteli J, Charles P (1993) "Treatment of psoriasis vulgaris with topical calcipotriol has no short-term effect on calcium or bone metabolism. A randomized, double- blind, placebo-controlled study." Acta Derm Venereol, 73, p. 300-4
  7. Murdoch D, Clissold SP (1992) "Calcipotriol. A review of its pharmacological properties and therapeutic use in psoriasis vulgaris." Drugs, 43, p. 415-29
  8. "Product Information. Dovonex (calcipotriene topical)." Westwood Squibb Pharmaceutical Corporation
View all 8 references

Calcipotriene topical drug interactions

There are 59 drug interactions with calcipotriene topical.

Report options

QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.